3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
85
Recurrence
9
Immunoglobulin Light-chain Amyloidosis
6
Neoplasms, Plasma Cell
3
Plasmacytoma
2
Lymphoma
2
Leukemia, Plasma Cell
2
Hematologic Neoplasms
2
Amyloidosis
2
Smoldering Multiple Myeloma
1
Proteostasis Deficiencies
1
POEMS Syndrome
1
Neoplasms
1
Neoplasm, Residual
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Hematologic Diseases
1
Genetic Diseases, Inborn
1
Chromosome 17 deletion
1
Alzheimer Disease
1
Interventions
Melphalan
2
sargramostim
1
keyhole-limpet hemocyanin
1
ixazomib
1
FANG vaccine
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genetic Diseases, Inborn
×
ixazomib
×
Plasma cell
×
Clear all
NCT03683277
2025-02-19
IFM2014-01
Intergroupe Francophone du Myelome
Phase 2
Terminated
26 enrolled